Michelino De Laurentiis
Michelino De Laurentiis
Istituto Nazionale Tumori Napoli "Fondazione Pascale", Napoli, ITALY
Verified email at istitutotumori.na.it
Title
Cited by
Cited by
Year
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 365 (9472), 1687-1717, 2005
63032005
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
52492005
Tamoxifen for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 351 (9114), 1451-1467, 1998
33151998
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 …
Early Breast Cancer Trialists' Collaborative Group
The Lancet 378 (9804), 1707-1716, 2011
27592011
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer
A Howell, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, ...
Lancet 365 (9453), 60-62, 2005
24182005
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
EBCTC Group
The lancet 378 (9793), 771-784, 2011
22352011
Polychemotherapy for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 352 (9132), 930-942, 1998
18781998
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
EBCTC Group
The Lancet 379 (9814), 432-444, 2012
16592012
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC …
A The
The Lancet 359 (9324), 2131-2139, 2002
16502002
Palbociclib in hormone-receptor–positive advanced breast cancer
NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ...
New England Journal of Medicine 373 (3), 209-219, 2015
12772015
Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 355 (9217), 1757-1770, 2000
10352000
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ...
New England Journal of Medicine 380 (7), 617-628, 2019
9242019
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
G Von Minckwitz, M Procter, E de Azambuja, D Zardavas, M Benyunes, ...
New England Journal of Medicine 377 (2), 122-131, 2017
9122017
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
Early Breast Cancer Trialists' Collaborative Group
New England journal of medicine 319 (26), 1681-1692, 1988
8561988
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1341-1352, 2015
8042015
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer: results of the ATAC …
ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group
Cancer 98 (9), 1802-1810, 2003
7442003
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
H Pan, R Gray, J Braybrooke, C Davies, C Taylor, P McGale, R Peto, ...
New England Journal of Medicine 377 (19), 1836-1846, 2017
7262017
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
G Di Lorenzo, G Tortora, FP D’Armiento, G De Rosa, S Staibano, ...
Clinical Cancer Research 8 (11), 3438-3444, 2002
5592002
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
C Carlomagno, F Perrone, C Gallo, M De Laurentiis, R Lauria, A Morabito, ...
Journal of Clinical Oncology 14 (10), 2702-2708, 1996
5551996
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
TY Kim, GM Kim, M Martín, C Zielinski, M Ruíz-borrego, E Carrasco, ...
Journal of Clinical Oncology, 32-45, 2019
5052019
The system can't perform the operation now. Try again later.
Articles 1–20